Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Deoxycytidine
  • Neoplasms

abstract

  • The suggested phase II dose on a continuous 42-day dosing schedule is 1,331 mg/m2/d. Linear pharmacologic parameters of the parent compound and metabolites are demonstrated.

publication date

  • May 1998

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 9586893

Additional Document Info

start page

  • 1795

end page

  • 802

volume

  • 16

number

  • 5